Observations on quality of life and disease control in patients with hereditary angioedema
We conclude that lanadelumab injection intervals can be generously individualized in many patients with HAE while fully maintaining disease control and QoL.
Authors
- Thomas Buttgereit (ORCID: https://orcid.org/0000-0002-9389-1767)
- Markus Magerl (ORCID: https://orcid.org/0000-0001-9218-5468)
- Annika Gutsche (ORCID: https://orcid.org/0000-0001-9120-1999)
Institutions
- Humboldt-Universität zu Berlin (DE)
- Fraunhofer Institute for Translational Medicine and Pharmacology (DE)
Publication Details
- Journal
- Skin Health and Disease
- Published
- 2025-07-25
- DOI
- https://doi.org/10.1093/skinhd/vzaf055
- Citations
- 1
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 1.63